Acrivon Therapeutics, Inc. (ACRV)

NASDAQ: ACRV · IEX Real-Time Price · USD
-0.35 (-2.72%)
At close: Dec 1, 2022 3:58 PM
+0.20 (1.60%)
After-hours: Dec 1, 2022 6:25 PM EST
Market Cap 273.19M
Revenue (ttm) n/a
Net Income (ttm) -19.82M
Shares Out 18.81M
EPS (ttm) -1.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 6,883
Open 12.52
Previous Close 12.85
Day's Range 12.4 - 12.76
52-Week Range 10.9 - 20.7
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About ACRV

Acrivon Therapeutics is a clinical stage biopharmaceutical company developing precision oncology medicines that we match to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing our proprietary proteomics-based patient responder identification platform. Our approach is designed to overcome the limitations of genomics-based patient selection methods. We do this by using our proprietary precision medicine platform, Acrivon Predictive Precision Proteomics, or AP3, to develop our pipeline of oncology drug candid... [Read more]

Industry Biotechnology
IPO Date Nov 15, 2022
CEO Peter Blume-Jensen, M.D., Ph.D.
Employees 35
Stock Exchange NASDAQ
Ticker Symbol ACRV
Full Company Profile

Financial Performance

Financial Statements


Acrivon Therapeutics Announces Pricing of Initial Public Offering

WATERTOWN, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncol...

2 weeks ago - GlobeNewsWire

Acrivon Therapeutics sets IPO price range

Acrivon Therapeutics Inc. on Thursday set an estimated price range of $16 to $18 a share in its upcoming initial public offering (IPO) on the Nasdaq under the symbol ACRV. With 5.9 million shares in the...

4 weeks ago - Market Watch